BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32777141)

  • 1. Neuroblastoma patient-derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response.
    Hee E; Wong MK; Tan SH; Choo Z; Kuick CH; Ling S; Yong MH; Jain S; Lian DWQ; Ng EHQ; Yong YFL; Ren MH; Syed Sulaiman N; Low SYY; Chua YW; Syed MF; Lim TKH; Soh SY; Iyer P; Seng MSF; Lam JCM; Tan EEK; Chan MY; Tan AM; Chen Y; Chen Z; Chang KTE; Loh AHP
    Cancer Sci; 2020 Oct; 111(10):3780-3792. PubMed ID: 32777141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax-based Rational Combinations are Effective in Models of
    Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
    Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
    Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
    Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
    Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
    Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
    Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
    Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
    J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.
    Wang T; Liu L; Chen X; Shen Y; Lian G; Shah N; Davidoff AM; Yang J; Wang R
    Cell Death Dis; 2018 Feb; 9(2):220. PubMed ID: 29445162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma.
    Hald ØH; Olsen L; Gallo-Oller G; Elfman LHM; Løkke C; Kogner P; Sveinbjörnsson B; Flægstad T; Johnsen JI; Einvik C
    Oncogene; 2019 Apr; 38(15):2800-2813. PubMed ID: 30542116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential anti-neuroblastoma agents from Juniperus oblonga.
    Qiao Y; Sunada NK; Hatada AE; Lange I; Khutsishvili M; Alizade V; Atha D; Ko'omoa-Lange DL; Borris RP
    Biochem Biophys Res Commun; 2019 Aug; 516(3):733-738. PubMed ID: 31255282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Targeting of
    Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
    Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.
    Liu M; Xia Y; Ding J; Ye B; Zhao E; Choi JH; Alptekin A; Yan C; Dong Z; Huang S; Yang L; Cui H; Zha Y; Ding HF
    Cell Rep; 2016 Oct; 17(2):609-623. PubMed ID: 27705805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an
    Orienti I; Farruggia G; Nguyen F; Guan P; Calonghi N; Kolla V; Chorny M; Brodeur GM
    Int J Nanomedicine; 2020; 15():6873-6886. PubMed ID: 32982239
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
    Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
    Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
    Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma.
    Huang CT; Hsieh CH; Lee WC; Liu YL; Yang TS; Hsu WM; Oyang YJ; Huang HC; Juan HF
    Clin Cancer Res; 2019 Jul; 25(13):4063-4078. PubMed ID: 30952635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN induces neuroblastoma in primary neural crest cells.
    Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
    Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.